|
Alterations in microarchitectural properties of cortical bone of the femur mid-diaphysis. |
||||
| Treatment |
Cortical Thickness (μm) |
Cortical Area (mm2) |
Medullary Area (mm2) |
Porosity (%) |
|
|
||||
| 0 IF Placebo |
0.187 ± 0.003 |
0.625 ± 0.001 |
0.010 ± 0.001 |
0.98 ± 0.28 |
| 0 IF LPS |
0.197 ± 0.003 |
0.646 ± 0.010 |
0.010 ± 0.002 |
0.84 ± 0.20 |
| 126 IF Placebo |
0.193 ± 0.002 |
0.628 ± 0.014 |
0.009 ± 0.001 |
1.07 ± 0.22 |
| 126 IF LPS |
0.191 ± 0.003 |
0.625 ± 0.008 |
0.012 ± 0.002 |
1.08 ± 0.31 |
| 504 IF Placebo |
0.194 ± 0.005 |
0.625 ± 0.014 |
0.010 ± 0.001 |
0.99 ± 0.24 |
| 504 IF LPS |
0.198 ± 0.001 |
0.652 ± 0.011 |
0.009 ± 0.001 |
0.86 ± 0.22 |
| P value |
||||
| LPS |
0.1340 |
0.1086 |
0.4386 |
0.6895 |
| IF |
0.4189 |
0.5571 |
0.5553 |
0.7637 |
| LPS*IF |
0.1293 |
0.3899 |
0.1988 |
0.9444 |
|
Mice were fed soy isoflavones (IF; 0, 126 or 504 mg aglycone equivalents of IF/kg diet; 0, Low or High, respectively) for 14-days prior to and during a 30-day exposure to LPS (1.33 μg/d). Results are expressed as means ± standard error. | ||||
Droke et al. Journal of Inflammation 2007 4:17 doi:10.1186/1476-9255-4-17 |
||||